BDBM175242 US11844801, Compound (M)-I::US9115089, 49

SMILES Cc1cnc(cc1-n1c(C)cc(OCc2ncc(F)cc2F)c(Cl)c1=O)-c1ccnc(n1)C(C)(C)O

InChI Key InChIKey=FQPQMJULRZINPV-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 175242   

TargetMAP kinase-activated protein kinase 2(Human)
Confluence Life Sciences

US Patent
LigandPNGBDBM175242(US9115089, 49 | US11844801, Compound (M)-I)
Affinity DataIC50: 21nMpH: 7.5Assay Description:The ability of compounds to inhibit activated phospho-p38alpha is evaluated using a p38alpha /MK2 and a p38alpha /PRAK cascade assay format. The kina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/12/2016
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 5(Human)
Confluence Life Sciences

US Patent
LigandPNGBDBM175242(US9115089, 49 | US11844801, Compound (M)-I)
Affinity DataIC50: 8.10E+3nMpH: 7.5Assay Description:The ability of compounds to inhibit activated phospho-p38alpha is evaluated using a p38alpha /MK2 and a p38alpha /PRAK cascade assay format. The kina...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/12/2016
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM175242(US9115089, 49 | US11844801, Compound (M)-I)
Affinity DataIC50: 21nMAssay Description:Inhibition of MK2 and PRAK by Compound (P)-I and (M)-I, respectively, was investigated to understand selectivity of Compound (P)-I and/or Compound (M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2024
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 5(Human)
Confluence Life Sciences

US Patent
LigandPNGBDBM175242(US9115089, 49 | US11844801, Compound (M)-I)
Affinity DataIC50: 8.10E+3nMAssay Description:Inhibition of MK2 and PRAK by Compound (P)-I and (M)-I, respectively, was investigated to understand selectivity of Compound (P)-I and/or Compound (M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2024
Entry Details
Go to US Patent

TargetMitogen-activated protein kinase 1(Human)
Aclaris Therapeutics

US Patent
LigandPNGBDBM175242(US9115089, 49 | US11844801, Compound (M)-I)
Affinity DataIC50: 3.48E+3nMAssay Description:Inhibition of MK2 and PRAK by Compound (P)-I and (M)-I, respectively, was investigated to understand selectivity of Compound (P)-I and/or Compound (M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2024
Entry Details
Go to US Patent

TargetMAP kinase-activated protein kinase 5(Human)
Confluence Life Sciences

US Patent
LigandPNGBDBM175242(US9115089, 49 | US11844801, Compound (M)-I)
Affinity DataIC50: 1.25E+4nMAssay Description:Inhibition of MK2 and PRAK by Compound (P)-I and (M)-I, respectively, was investigated to understand selectivity of Compound (P)-I and/or Compound (M...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/8/2024
Entry Details
Go to US Patent